Author(s)

Jun Sun, Bo Ma, Xinyu Cui, Jie Bao, Lei Lei, Ling Li, Lili Bi, Lina Wang

Corresponding Author

Jun Sun

Abstract

Objective: To compare the clinical efficacy of pirarubicin, dexamethasone plus thalidomide (PDT regimen) with vincristine, doxorubicin plus dexamethasone (VAD regimen) in patients with multiple myeloma (MM). Methods: Thirty-six patients with multiple myeloma were randomly divided into the control group (n=18) and the observation group (n=18). The control group was treated with PDT. The observation group was treated with VAD. After treatment, the therapeutic effects of the two groups were compared. Result: The total effective rate is 66.67% in the PDT group and 61.11% in the VAD group. There was no statistical significance (P>0.05). The adverse reactions in the PDT group were smaller than those in the VAD group, and the difference was statistically significant (P<0.05). Conclusion: The PDT regimen is a treatment for multiple myeloma. The therapeutic effect is better, and the incidence of cardiotoxicity and peripheral neuritis is significantly reduced. Further improvement of various clinical indicators is worthy of clinical promotion.

Keywords

Multiple Myeloma, Pdt, Vad